title: [Antiphospholipid antibodies: their prevalence, clinical significance and correlation with cytokine levels in acute myeloid leukemia and non-Hodgkin's lymphoma].
abstract: Forty-five patients with de novo acute myeloid leukemia (AML) and 22 patients with newly-diagnosed non-Hodgkin lymphoma (NHL) were investigated. Tests for antiphospholipid antibodies (APA) included the measurement of anticardiolipin antibodies (aCL) with a solid-phase immunoassay, and the detection of the lupus-like anticoagulant (LA) activity. Fifteen patients with AML (33.3%) and 9 patients with non-Hodgkin lymphoma (40.9%) presented elevated APA at diagnosis, as compared to 3 out of 174 persons of the control group (p < 0.0001). APA titles became normal in all patients responding to treatment, whereas non-responders retained elevated levels. In addition, 2 patients (1 with AML and 1 with NHL) who had normal APA at diagnosis and were either refractory to treatment or in relapse, subsequently developed LA and/or aCL positivity. At presentation, the mean levels of IgG- and IgM-aCL in patients were not significantly different from controls, and concordance between aCL and LA results reached just 12%. With regard to the clinical course, we were not able to detect any statistically significant difference between patients with normal and elevated APA. Pretreatment concentrations of IL-6 and TNF-alpha in AML, and soluble form of the receptor for interleukin-2 (sIL-2r) in NHL were found significantly elevated compared to controls (p < 0.001, p = 0.011 and p = 0.016 respectively). In addition, the levels of these cytokines correlated with IgG-aCL at the different times of laboratory investigations. These results demonstrate that APA may have a role as markers of disease activity and progression in some haematological malignancies.
authors.affiliation: Divisione di Ematologia, Università Tor Vergata, Ospedale S. Eugenio, Roma.
authors.forename: A
authors.initials: A
authors.lastname: Sciarra
authors.forename: R
authors.initials: R
authors.lastname: Stasi
authors.forename: E
authors.initials: E
authors.lastname: Stipa
authors.forename: M
authors.initials: M
authors.lastname: Masi
authors.forename: F
authors.initials: F
authors.lastname: Oliva
authors.forename: M
authors.initials: M
authors.lastname: Olivieri
authors.forename: A
authors.initials: A
authors.lastname: Perrotti
authors.forename: G
authors.initials: G
authors.lastname: Zaccari
authors.forename: S
authors.initials: S
authors.lastname: Amadori
authors.forename: G
authors.initials: G
authors.lastname: Papa
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D017152:Antibodies, Antiphospholipid / Q000097:blood* / Q000187:drug effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016009:Chi-Square Distribution; D016207:Cytokines / Q000097:blood* / Q000187:drug effects; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D007951:Leukemia, Myeloid / Q000097:blood* / Q000188:drug therapy; D008228:Lymphoma, Non-Hodgkin / Q000097:blood* / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D018709:Statistics, Nonparametric
chemical_list: D017152:Antibodies, Antiphospholipid; D016207:Cytokines
vernacular_title: Anticorpi anti-fosfolipidi: prevalenza, significato clinico e correlazione con i livelli di citochine nella leucemia mieloide acuta e nel linfoma non-Hodgkin.